Literature DB >> 23706365

Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats.

Zhen Yang1, Xin Yu, Li Cheng, Li-yan Miao, Hong-xia Li, Lian-hua Han, Wen-ping Jiang.   

Abstract

BACKGROUND: The discovery of angiotensin-converting enzyme 2 (ACE2) has greatly modified understanding of the renin-angiotensin system (RAS). AIMS: To investigate the cardiac expression of ACE2 and ACE in spontaneously hypertensive rats (SHRs) and the effects of enalapril on them.
METHODS: Fifteen SHRs were randomly assigned to two groups: an SHR control group (n=7), treated with vehicle; and an enalapril group (n=8), treated with enalapril (15 mg/kg/day). After 4 weeks of treatment, the rats were killed and the left ventricular tissue was dissected. Reverse transcription-polymerase chain reaction and Western blot protein staining were performed to detect expression of ACE2 and ACE messenger ribonucleic acid (mRNA) and protein. Ten Wistar Kyoto rats (WKYs) served as the normotensive control group, which were treated with vehicle.
RESULTS: Compared with in normotensive WKYs, cardiac expression of ACE mRNA and protein in SHRs was increased (1.68±0.34 vs. 0.33±0.12, P<0.05 and 1.21±0.14 vs. 0.71±0.11, P<0.05, respectively), whereas cardiac expression of ACE2 mRNA and protein was decreased (0.50±0.15 vs. 1.16±0.24, P<0.05 and 0.71±0.24 vs. 1.22±0.14, P<0.05, respectively). After treatment with enalapril, the levels of ACE mRNA and protein were decreased (0.44±0.19 vs. 1.68±0.34, P<0.01 and 0.87±0.13 vs. 1.21±0.14, P<0.05, respectively), the level of ACE2 mRNA was increased (1.77±0.49 vs. 0.50±0.15, P<0.05) but the level of ACE2 protein remained unchanged.
CONCLUSIONS: In SHRs, the expression of cardiac ACE was remarkably increased, whereas ACE2 was notably decreased. Reduction of ACE and elevation of ACE2 might be one of the mechanisms underlying the antihypertensive function of enalapril.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23706365     DOI: 10.1016/j.acvd.2013.01.004

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  12 in total

1.  Chronic enalapril treatment increases transient outward potassium current in cardiomyocytes isolated from right ventricle of spontaneously hypertensive rats.

Authors:  Luiz Fernando Rodrigues Junior; Ana Carolina de Azevedo Carvalho; Enildo Broetto Pimentel; José Geraldo Mill; José Hamilton Matheus Nascimento
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-03       Impact factor: 3.000

2.  Insufficient hypothalamic angiotensin-converting enzyme 2 is associated with hypertension in SHR rats.

Authors:  Kun Wang; Yuanyuan Xu; Weiwei Yang; Yuanshu Zhang
Journal:  Oncotarget       Date:  2017-03-21

3.  Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study.

Authors:  Y Cen; X Chen; Y Shen; X-H Zhang; Y Lei; C Xu; W-R Jiang; H-T Xu; Y Chen; J Zhu; L-L Zhang; Y-H Liu
Journal:  Clin Microbiol Infect       Date:  2020-06-09       Impact factor: 8.067

4.  Pathological cardiac remodeling occurs early in CKD mice from unilateral urinary obstruction, and is attenuated by Enalapril.

Authors:  Onju Ham; William Jin; Lei Lei; Hui Hui Huang; Kenji Tsuji; Ming Huang; Jason Roh; Anthony Rosenzweig; Hua A Jenny Lu
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379

Review 5.  Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.

Authors:  Muchtaridi Muchtaridi; M Fauzi; Nur Kusaira Khairul Ikram; Amirah Mohd Gazzali; Habibah A Wahab
Journal:  Molecules       Date:  2020-09-01       Impact factor: 4.411

6.  Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.

Authors:  Victor Gustavo Balera Brito; Mariana Sousa Patrocinio; Maria Carolina Linjardi de Sousa; Ayná Emanuelli Alves Barreto; Sabrina Cruz Tfaile Frasnelli; Vanessa Soares Lara; Carlos Ferreira Santos; Sandra Helena Penha Oliveira
Journal:  Front Pharmacol       Date:  2020-11-11       Impact factor: 5.810

Review 7.  From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension.

Authors:  Sheila K Patel; Elena Velkoska; Melanie Freeman; Bryan Wai; Terase F Lancefield; Louise M Burrell
Journal:  Front Physiol       Date:  2014-06-24       Impact factor: 4.566

Review 8.  Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence.

Authors:  Krishna Sriram; Paul A Insel
Journal:  Clin Pharmacol Ther       Date:  2020-05-10       Impact factor: 6.903

9.  Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: A case-control study.

Authors:  Qi Zhang; Mingyu Cong; Ningning Wang; Xueyan Li; Hao Zhang; Keyong Zhang; Ming Jin; Nan Wu; Changchun Qiu; Jingping Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

10.  Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.

Authors:  Hajira Dambha-Miller; Ali Albasri; Sam Hodgson; Christopher R Wilcox; Shareen Khan; Nazrul Islam; Paul Little; Simon J Griffin
Journal:  BMJ Open       Date:  2020-09-14       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.